Advancing Cancer Detection with Mainz Biomed's Latest Study
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples
This Study is Set to Report Top-Line Results in Late 2025
Mainz Biomed N.V. (NASDAQ:MYNZ), a pioneering molecular genetics diagnostic firm focused on early cancer detection, has made significant strides by enrolling its first patient in the innovative eAArly DETECT 2 study. This critical trial aims to assess the efficacy of the Company’s state-of-the-art colorectal cancer (CRC) test, which integrates proprietary mRNA biomarkers and advanced technology like an AI-driven algorithm along with a FIT test. This study focuses on a population of approximately 2,000 average-risk patients, validating the outstanding results from previous studies and transitioning CRC screening towards proactive prevention.
The eAArly DETECT 2 study plans to complete its enrollment by the latter half of 2025, with Mainz Biomed targeting the revelation of pivotal top-line results by the same year’s fourth quarter. Depending on the outcomes, the Company anticipates finalizing its protocols for its upcoming U.S. pivotal study, ReconAAsense, set to begin in 2026. The advanced CRC and APL test will not only highlight the presence of cancerous lesions but also aims to avert the disease through timely detection of precancerous adenomas, representing a leap forward in patient care.
Guido Baechler, Chief Executive Officer of Mainz Biomed, expressed his enthusiasm regarding the first patient milestone, marking the culmination of intense preparatory efforts to ensure the trial's success. He emphasized the significance of this clinical trial for patients and medical professionals, stating that precise identification of advanced precancerous lesions and early-stage CRC is central to their mission, aiming to eliminate colorectal cancer and lower global mortality rates associated with this disease.
The innovative mRNA biomarkers, sourced from Sherbrooke University in 2022, exhibit an outstanding capacity to detect advanced adenomas—treatable precancerous colonic polyps—and early-stage CRC. Through the eAArly DETECT 2 study, the effectiveness of these biomarkers will be rigorously evaluated alongside Mainz Biomed’s proprietary algorithm, thus refining product specifications and enhancing diagnostic sensitivity and specificity for early-stage CRC.
Stay Informed About Mainz Biomed
To learn more about Mainz Biomed and its innovative solutions, keep an eye on external channels for further updates.
About Mainz Biomed NV
Mainz Biomed is committed to developing groundbreaking molecular genetic diagnostic systems for critical health conditions. Their flagship product, ColoAlert, is specifically designed for the early detection of colorectal cancer, marketed across Europe. The Company is also advancing the development of its next-generation CRC screening test, poised for pivotal FDA approval studies in the U.S. Additionally, Mainz Biomed's portfolio includes PancAlert, designed for early detection of pancreatic cancer through a specialized PCR test. To explore more about their mission and projects, visit mainzbiomed.com or follow them on their social media platforms.
If you have any media inquiries, please reach out to:
MC Services AG
Anne Hennecke / Maximilian Schur
+49 211 529252 17
mainzbiomed@mc-services.eu
If you are an investor or have related inquiries, please contact: ir@mainzbiomed.com
Frequently Asked Questions
What is the eAArly DETECT 2 study?
The eAArly DETECT 2 study is a clinical trial launched by Mainz Biomed to evaluate their next-generation colorectal cancer test, aiming to enhance early detection of cancer.
How many patients are involved in the study?
The study plans to involve approximately 2,000 average-risk patients to ensure comprehensive data gathering and analysis.
When are the results of the study expected?
Mainz Biomed aims to report top-line results from the study by the fourth quarter of 2025.
What technologies are being utilized in the study?
The study combines proprietary mRNA biomarkers, an AI-driven algorithm, and a FIT test for improved detection of precancerous lesions and early-stage cancer.
What is the significance of this study?
This study represents a key step forward in colorectal cancer prevention and aims to enhance the accuracy of early cancer detection, potentially saving lives.
